This announcement is a separate document:
中國再生醫學:終止(1)建議遷冊;(2)建議採納存續大綱及新細則;(3)建議減少股份溢價賬;(4)建議股本重組;及(5)建議變更每手買賣單位
CRMI: TERMINATION OF (1) PROPOSED CHANGE OF DOMICILE; (2) PROPOSED ADOPTION OF MEMORANDUM OF CONTINUANCE AND NEW BYE-LAWS; (3) PROPOSED REDUCTION OF SHARE PREMIUM ACCOUNT; (4) PROPOSED CAPITAL REORGANISATION; AND (5) PROPOSED CHANGE IN BOARD LOT SIZE
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.